Capecitabine or Infusional 5-fluorouracil for Gastroesophageal Cancer: A Cost–Consequence Analysis
نویسندگان
چکیده
منابع مشابه
Capecitabine or 5fu for Gastroesophageal Cancer
Globally, gastric and esophageal cancers are, respectively, the 2nd and 6th most common causes of cancer-related deaths; they are also an important cause of cancer-related morbidity 1. Surgical resection remains the definitive curative treatment for earlystage disease; however, most patients present with inoperable or metastatic disease. Consequently, overall 5-year survival rates are in the ra...
متن کاملInfusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer.
PURPOSE This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma. MATERIALS AND METHODS Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. T...
متن کاملAdjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
PURPOSE Chemotherapy and radiotherapy are approved in clinical practice of adjuvant treatment of gastric carcinoma. In present study, we retrospectively evaluated the efficacy and tolerability of an adjuvant treatment protocol including bi-weekly cisplatin, infusional 5-fluorouracil (5-FU) and folinic acid followed by continuous 5-FU infusion during radiotherapy. PATIENTS AND METHODS Between ...
متن کاملContinuous infusional 5-fluorouracil in breast cancer or the revival of an old drug?
Editorial Continuous infusional 5-fluorouracil in breast cancer or the revival of an old drug? Sometimes the old drugs may still be the best. 5-Flu-orouracil (5-FU) was synthesised by Heidelberger in 1957 [1] and quickly went into clinical trials. Despite all the subsequent developments in cancer chemotherapy, it is still our most widely prescribed cytotoxic drug, mainly because of its central ...
متن کاملIrinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
BACKGROUND The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P). PATIENTS AND METHODS Patients were randomly assigned to recei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Oncology
سال: 2011
ISSN: 1718-7729
DOI: 10.3747/co.v18i2.730